| |
| [Milestones] [
Archived section of News] |
| |
- Completion of Phase I/II HCC study
|
August |
2007 |
- Series F funding contract signed
|
May |
2007 |
- Completion of Phase I and II patient recruitment for HCC
|
January |
2007 |
- FDA Meeting on Botanical Quality Control
|
October |
2006 |
- Signed Licensing & Co-development Agreement with TTY Biopharm Co. of Taiwain
|
September |
2006 |
- PHY906 patent granted in U.S.
|
April |
2006 |
- Series E funding completed
|
April |
2006 |
- Phytomics patent granted in Australia
|
June |
2005 |
- PHY906 patent granted in Singapore
|
April |
2005 |
- PHY906 Patent allowed in South Korea
|
January |
2005 |
- NIH SBIR Phase II Grant for " Genomic Bioresponse: Quality Control
Botanical Drugs."
|
October |
2004 |
- NIH SBIR Phase I Grant or " Enhancement of Capecitabine by PHY906
in Liver Cancer"
|
September |
2004 |
- PhytomicsQC licensed to Sinphar Pharmaceuticals
|
June |
2004 |
- PhytomicsQC patent granted in Singapore
|
June |
2004 |
- Formation of TCM Consortium
|
December |
2003 |
- PHY906 + capecitabine Phase I/II liver Cancer study commenced
|
November |
2003 |
- NCCAM SBIR Phase I grant for "LC/MS: Molecular Fingerprint for
Botanical Drugs".
|
August |
2003 |
- NIH SBIR Phase I grant or " Genomic Bioresponse: Quality control for
Botanical Drugs."
|
September |
2002 |
- PHY906 + CPT -11/5-FU/LV or PHY906 + CPT - 11 Phase I/II colorectal
cancer study launched
|
February |
2002 |
- PHY906 IND application approved by FDA
|
August |
2001 |
|
August |
2000 |
- Seed Round over U.S. $4 million raised
|
June |
1999 |
- Development of PHY906 initiated
|
March |
1999 |
|
September |
1998 |
